Literature DB >> 17264672

Proteomic comparison of oligodendrogliomas with and without 1pLOH.

Hiroaki Okamoto1, Jie Li, Sven Gläsker, Alexander O Vortmeyer, Howard Jaffe, R Aaron Robison, Oliver Bogler, Tom Mikkelsen, Irina A Lubensky, Edward H Oldfield, Zhengping Zhuang.   

Abstract

OBJECTIVE: Chemoresistance is a widespread therapeutic challenge in glial tumors. The molecular basis of chemoresistance is poorly understood, precluding advances in glioma treatment and leaving gliomas among the most lethal tumors. Oligodendrogliomas provide a unique model to study the molecular basis of chemoresistance, as there are two distinct genetic subtypes with significant differences in chemosensitivity. Despite a high morphological similarity, tumors with allelic loss on the short arm of chromosome 1 (1pLOH) are more chemosensitive than those without 1pLOH.
METHODS: In order to identify candidate proteins potentially responsible for glioma chemosensitivity, we compared the proteome of four oligodendrogliomas with and five without 1pLOH using comparative proteomic profiling. Proteomic analysis was performed by two-dimensional protein gel electrophoresis and subsequent computerized gel analysis for detection of distinguishing patterns of protein expression. Differentially expressed proteins were identified using Liquid Chromatography/Mass Spectrometry. Differential expression of select proteins was confirmed by Western blotting.
RESULTS: We identified seven candidate proteins that are overexpressed in oligodendrogliomas without 1pLOH. Two of these proteins (glyoxalase I and Rho GDP dissociation inhibitor) have previously been shown to enhance chemoresistance in other tumors. In turn, we identified twelve overexpressed proteins in tumors with 1pLOH that have previously been reported to induce chemosensitivity in other forms of human neoplasia.
CONCLUSIONS: These identified proteins are potential targets for pharmacological therapy and may also be useful as biomarkers for differentiation of chemoresistant and chemosensitive oligodendroglioma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17264672     DOI: 10.4161/cbt.6.3.3731

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

1.  Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion.

Authors:  Robert C Rostomily; Donald E Born; Richard P Beyer; Jinghua Jin; Ellsworth C Alvord; Andrei M Mikheev; Russell T Matthews; Catherine Pan; Leila Khorasani; Josh A Sonnen; Thomas J Montine; Min Shi; Jing Zhang
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

Review 2.  Proteomics of gliomas: initial biomarker discovery and evolution of technology.

Authors:  Juliya Kalinina; Junmin Peng; James C Ritchie; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2011-09       Impact factor: 12.300

3.  Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q.

Authors:  Michael Grzendowski; Marietta Wolter; Markus J Riemenschneider; Christiane B Knobbe; Uwe Schlegel; Helmut E Meyer; Guido Reifenberger; Kai Stühler
Journal:  Neuro Oncol       Date:  2010-01-07       Impact factor: 12.300

4.  Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents.

Authors:  Jeffrey Helgager; Jie Li; Irina A Lubensky; Russell Lonser; Zhengping Zhuang
Journal:  J Oncol       Date:  2010-05-04       Impact factor: 4.375

5.  Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.

Authors:  Carl Wibom; Lina Mörén; Mads Aarhus; Per Morten Knappskog; Morten Lund-Johansen; Henrik Antti; A Tommy Bergenheim
Journal:  J Neurooncol       Date:  2009-04-07       Impact factor: 4.130

6.  Proteomic analysis of glioma chemoresistance.

Authors:  Kyoungho Suk
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

7.  A unique four-hub protein cluster associates to glioblastoma progression.

Authors:  Pasquale Simeone; Marco Trerotola; Andrea Urbanella; Rossano Lattanzio; Domenico Ciavardelli; Fabrizio Di Giuseppe; Enrica Eleuterio; Marilisa Sulpizio; Vincenzo Eusebi; Annalisa Pession; Mauro Piantelli; Saverio Alberti
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.